1. Home
  2. NUV vs KARD Comparison

NUV vs KARD Comparison

Compare NUV & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Value Fund Inc.

NUV

Nuveen Municipal Value Fund Inc.

N/A

Current Price

$8.08

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$11.56

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NUV
KARD
Founded
1987
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
NUV
KARD
Price
$8.08
$11.56
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $41.00
AVG Volume (30 Days)
★ 1.3M
441.3K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 3.96%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.02
$12.23
52 Week High
$9.26
$27.00

Technical Indicators

Market Signals
Indicator
NUV
KARD
Relative Strength Index (RSI) 37.22 35.74
Support Level $8.05 N/A
Resistance Level $8.34 $16.26
Average True Range (ATR) 0.09 1.30
MACD -0.03 -0.24
Stochastic Oscillator 7.14 0.60

Price Performance

Historical Comparison
NUV
KARD

About NUV Nuveen Municipal Value Fund Inc.

Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: